Alibaba Health Information Technology Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Alibaba Health Information Technology wird ein jährliches Gewinn- und Umsatzwachstum von 19.6% bzw. 11.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.1% betragen.
Wichtige Informationen
23.2%
Wachstumsrate der Gewinne
23.1%
EPS-Wachstumsrate
| Consumer Retailing Gewinnwachstum | 27.9% |
| Wachstumsrate der Einnahmen | 11.0% |
| Zukünftige Eigenkapitalrendite | 13.5% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 08 Jul 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03
After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 39,491 | 2,543 | 3,100 | 3,344 | 11 |
| 3/31/2026 | 36,018 | 1,914 | 2,343 | 2,499 | 15 |
| 3/31/2025 | 31,266 | 1,605 | 1,829 | 1,803 | 13 |
| 3/31/2024 | 27,027 | 883 | 1,080 | 1,080 | N/A |
| 12/31/2023 | 27,623 | 850 | 862 | 871 | N/A |
| 9/30/2023 | 28,218 | 817 | 644 | 662 | N/A |
| 6/30/2023 | 27,491 | 675 | 447 | 459 | N/A |
| 3/31/2023 | 26,763 | 533 | 250 | 256 | N/A |
| 12/31/2022 | 24,742 | 332 | 284 | 293 | N/A |
| 9/30/2022 | 22,720 | 128 | 318 | 331 | N/A |
| 6/30/2022 | 21,649 | -69 | 363 | 378 | N/A |
| 3/31/2022 | 20,578 | -266 | 409 | 424 | N/A |
| 12/31/2021 | 19,146 | -216 | 714 | 733 | N/A |
| 9/30/2021 | 17,714 | -167 | 1,018 | 1,041 | N/A |
| 6/30/2021 | 16,616 | 91 | 1,005 | 1,025 | N/A |
| 3/31/2021 | 15,518 | 349 | 992 | 1,009 | N/A |
| 12/31/2020 | 14,080 | 313 | 830 | 842 | N/A |
| 9/30/2020 | 12,642 | 278 | 668 | 674 | N/A |
| 6/30/2020 | 11,119 | 136 | 619 | 629 | N/A |
| 3/31/2020 | 9,596 | -7 | 570 | 584 | N/A |
| 12/31/2019 | 8,465 | -3 | 564 | 577 | N/A |
| 9/30/2019 | 7,334 | 1 | 558 | 570 | N/A |
| 6/30/2019 | 6,215 | -40 | 474 | 483 | N/A |
| 3/31/2019 | 5,096 | -82 | 390 | 396 | N/A |
| 12/31/2018 | 4,264 | -91 | 367 | 373 | N/A |
| 9/30/2018 | 3,432 | -100 | 344 | 349 | N/A |
| 6/30/2018 | 2,937 | -104 | 134 | 139 | N/A |
| 3/31/2018 | 2,443 | -107 | -76 | -70 | N/A |
| 12/31/2017 | 1,876 | -152 | N/A | -157 | N/A |
| 9/30/2017 | 1,310 | -196 | N/A | -244 | N/A |
| 6/30/2017 | 892 | -202 | N/A | -235 | N/A |
| 3/31/2017 | 475 | -208 | N/A | -226 | N/A |
| 12/31/2016 | 285 | -201 | N/A | -186 | N/A |
| 9/30/2016 | 94 | -194 | N/A | -145 | N/A |
| 6/30/2016 | 76 | -193 | N/A | -131 | N/A |
| 3/31/2016 | 57 | -192 | N/A | -117 | N/A |
| 12/31/2015 | 44 | -173 | N/A | -118 | N/A |
| 9/30/2015 | 32 | -154 | N/A | -119 | N/A |
| 6/30/2015 | 31 | -118 | N/A | -87 | N/A |
| 3/31/2015 | 30 | -81 | N/A | -55 | N/A |
| 12/31/2014 | 31 | -60 | N/A | -8 | N/A |
| 9/30/2014 | 31 | -39 | N/A | 38 | N/A |
| 6/30/2014 | 27 | -36 | N/A | 20 | N/A |
| 3/31/2014 | 22 | -31 | N/A | 1 | N/A |
| 12/31/2013 | 16 | -35 | N/A | -26 | N/A |
| 9/30/2013 | 12 | -39 | N/A | -55 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 241Das prognostizierte Gewinnwachstum (19.6% pro Jahr) liegt über der Sparquote (2.2%).
Ertrag vs. Markt: 241Die Erträge des Unternehmens (19.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (12% pro Jahr).
Hohe Wachstumserträge: 241Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: 241Die Einnahmen des Unternehmens (11.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).
Hohe Wachstumseinnahmen: 241Die Einnahmen des Unternehmens (11.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 241Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.1 %).